2026-04-17T21:27:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4706192024-11-21T01:53:06Zcom_2072_98col_2072_378192

Increase of Circulating Monocyte-Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage Mariscal, Anaís Zamora, Carlos Díaz Torne, César Ortiz, M. Àngels De Agustin, Juan Jose Reina, Delia Estrada, Paula Moya, Patricia Corominas, Hèctor Vidal, Silvia Platelets Monocytes Rheumatoid arthritis Tocilizumab Immune modulation Inflammation Immunity Platelets (PLT) bind to a significant percentage of circulating monocytes and this im-munomodulatory interaction is increased in several inflammatory and autoimmune conditions. The therapeutic blockage of IL-6 with Tocilizumab (TCZ) alters PLT and the phenotype and function of monocytes in rheumatoid arthritis (RA). However, the relationship between monocyte-PLT conjugates (CD14+PLT+) and clinical and immunological variables and the regulation of this interaction by IL-6 blockage are still unknown. Here, we compared the presence of monocyte-PLT conjugates (CD14+PLT+) and membrane CD162 expression using flow cytometry, and, by ELISA, the markers of PLT activation (sCD62P and sCD40L) in healthy donors (HD) and patients with long-standing RA before TCZ (baseline). We found higher percentages and absolute counts of CD14+PLT+, and higher plasmatic levels of sCD62P and sCD40L but lower CD162 expression on monocytes from RA patients than those from HD. Additionally, the levels of CD14+PLT+ inversely correlated with inflammatory parameters. Interestingly, 95% of patients with lower percentages of CD14+PLT+ and only 63% of patients with higher percentages of CD14+PLT+ achieved a EULAR-defined response at four weeks (p = 0.036). After TCZ, the percentage of CD14+PLT+ increased in 92% of RA patients who achieved 12 w-remission (p < 0.001). Our results suggest that the binding of PLTs has a modulatory effect, accentuated by the increased binding of PLTs to monocytes in response to the therapeutic blockage of IL-6. 2022 Article https://ddd.uab.cat/record/283215 urn:10.3390/ijms23105748 urn:oai:ddd.uab.cat:283215 urn:scopus_id:85130299870 urn:articleid:14220067v23n10p5748 urn:pmid:35628558 urn:pmc-uid:9144642 urn:pmcid:PMC9144642 urn:oai:pubmedcentral.nih.gov:9144642 urn:oai:egreta.uab.cat:publications/73516b56-2e59-4d50-b123-751887e12544 eng Instituto de Salud Carlos III PI17/00072 Instituto de Salud Carlos III PI20/00184 International journal of molecular sciences ; Vol. 23 Núm. 10 (May 2022), p. 5748 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf